PETROSCRAPS.COM

Silence Therapeutics – PF-04523655 Phase 2 Study Results Silence Therapeutics – PF-04523655 Phase 2 Study Results Read more on AFX CNF Finance Regulatory News via Yahoo! UK & Ireland…. Click Here to Read More

PsiOxus Therapeutics Initiates Phase II Clinical Study of Wasting Disease Therapeutic MT-102 LONDON–(BUSINESS WIRE)–PsiOxus Therapeutics, Ltd. (PsiOxus) announced initiation of a Phase II study of MT-102, a small molecule therapeutic for the treatment of cancer- and age-related wasting. MT-102 is being developed to reverse the effects of cachexia, a wasting disease that accompanies cancer, heart failure, COPD, renal failure, cirrhosis and rheumatoid arthritis, and that is associated … Read more on Business…. Click Here to Read More

PolyMedix Receives Phase 2 NIH Grant to Develop a Novel Antimicrobial Defensin Mimetic for Oral Candidiasis RADNOR, Pa.—-PolyMedix, Inc. , an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has received a Phase 2 grant in the amount of $986,000 from the National Institute of Health to support the development of defensin mimetic antimicrobial compounds for the treatment of oral candidiasis. Read more on Business Wire via Yahoo!…. Click Here to Read More

Reportlinker Adds Advanced Phase Change Materials (PCM) Market: Global Forecast (2010-2015) Reportlinker.com announces that a new market research report is available in its catalogue: Read more on PR Newswire via Yahoo!…. Click Here to Read More

PolyMedix to Review Results from Recent Phase 1B LMWH Reversal Clinical Study with Heptagonist PMX-60056 RADNOR, Pa.—-PolyMedix, Inc. , an emerging bio-technology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has scheduled a webcast for Wednesday, June 9 at 4:00 PM Eastern Time. Read more on Business Wire via Yahoo!…. Click Here to Read More

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer Amgen today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology Annual Meeting. Read more on…. Click Here to Read More